Journal article

The mTORC1 Inhibitor Everolimus Prevents and Treats E mu-Myc Lymphoma by Restoring Oncogene-Induced Senescence

Meaghan Wall, Gretchen Poortinga, Kym L Stanley, Ralph K Lindemann, Michael Bots, Christopher J Chan, Megan J Bywater, Kathryn M Kinross, Megan V Astle, Kelly Waldeck, Katherine M Hannan, Jake Shortt, Mark J Smyth, Scott W Lowe, Ross D Hannan, Richard B Pearson, Ricky W Johnstone, Grant A McArthur


Related Projects (11)


Awarded by National Health and Medical Research Council of Australia

Funding Acknowledgements

R.W. Johnstone has a commercial research grant and has received honoraria for service on the speakers' bureau for Novartis. G. A. McArthur has commercial research grants from Novartis and Pfizer. No potential conflicts of interest were disclosed by the other authors.This work was supported by grants from the National Health and Medical Research Council of Australia to R. D. Hannan (166908 and 251688), R. B. Pearson (509087 and 400116), M.J. Smyth (454569), R.W. Johnstone (251608 and 566702), and G. A. McArthur (400120 and 566876) and from Cancer Council Victoria (to M. Wall, R. B. Pearson, and R. W. Johnstone), the Leukaemia Foundation of Australia (to C.J. Chan, R. W. Johnstone, and R. D. Hannan), the Victorian Cancer Agency (to M. Wall and R. W. Johnstone), the Susan G. Komen for the Cure Foundation (to R. W. Johnstone), the Australian Rotary Health Foundation (to R. W. Johnstone), and the National Cancer Institute (to S. W. Lowe). G. A. McArthur received the Sir Edward Dunlop Fellowship of the Cancer Council of Victoria.